Rocket Pharmaceuticals Debt

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a Cranbury, N.J.-based fully integrated, commercial-stage biotechnology company focused on genetic medicines for rare inherited cardiovascular disorders, entered into a credit facility agreement for up to $150.0M in debt financing with Hercules Capital, Inc. (NYSE: HTGC). The company said the facility strengthens its financial position and provides access to additional capital to support execution, with the excerpt truncated after "support executi" and no further use-of-proceeds or expansion plans detailed. The announcement does not characterize the facility as a first or follow-on round and discloses no specific metrics on revenue, clients, pipeline progress, or employee count, with Hercules Capital as the sole disclosed lender.